Skip to main content

Dr Sundus Yahya

Consultant Clinical Oncologist

MBBS, FRCR, MSc, MRCP

Practises at: The Priory Hospital

Sundus-Yahya-Oncology

Personal Profile

Dr Sundus Yahya is a Consultant Clinical Oncologist at the Priory Hospital.

After her medical degree, Dr Yahya was trained at Mersey and North West region, with clinical oncology training within West Midlands region. She obtained her Masters in Clinical Oncology from the University of Birmingham during specialist training. Dr Yahya was also awarded RCR cyclotron fellowship to learn about Proton therapy, from University of Florida Health Proton Therapy Institute (2016).

She holds a substantive post at Queen Elizabeth Hospital, University Hospitals Birmingham as Consultant Clinical Oncologist, Radiotherapy Service Lead and MSCC Lead. She has previously been M&M lead for cancer services (March 2019-Dec 2020) and Medical Tribunal member of the First-tier Tribunal, Social Entitlement Chamber (Social Security and Child Support), Judicial Office, UK (May 2018- Dec 2018).

She is GMC accredited trainer and is passionate about teaching and training. She also delivered oncology training in in low/middle income countries through RCR International Travelling Fellowship (2017-2019). She is trained to deliver stereotactic radiotherapy employing cyberknife/VMAT and is actively involved in breast and lung cancer clinical trials as Principal and Co-investigator. 

She holds a substantive post at Queen Elizabeth Hospital, University Hospitals Birmingham as Consultant Clinical Oncologist and MSCC Lead and had been Radiotherapy Service Lead (2021-2023)

 

Clinical Interests

  • Stereotactic Radiosurgery (SRS) and SABR, Cyber Knife and Linac based Platforms (lung, bones, spine, lymph nodes)
  • Intensity Modulated Radiotherapy (IMRT), VMAT (Volumetric modulated arc therapy)
  • 3D Conformal radiotherapy planning
  • Chemotherapy (adjuvant, neo-adjuvant and palliative) initiation and review
  • Concurrent chemoradiotherapy
  • Immunotherapy (Initiation, maintenance & management of toxicity)
  • Targetted therapy
Clinical Trials – Radiotherapy, Immunotherapy, Chemotherapy
i